BSE filing, BSE: 544365. Summary written from the filing by ALFA Finder's alert engine.
Shanmuga Hospital Ltd: key numbers
- Share price
- ₹41.05
- Market cap
- ₹55.88 Cr
- Revenue (annual)
- ₹47.44 Cr
- Net profit (annual)
- ₹4.21 Cr
- P/E (TTM)
- 13.3×Sector 51.1×
- Promoter holding
- 72.35%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shanmuga Hospital Ltd
All →Shanmuga Hospital Product Launch
Shanmuga Hospital commercially launched its 'Shanmuga 360' healthcare mobile app on 20 October 2026. It offers medicine booking, lab tests, ambulance and home-care services.
Shanmuga Hospital Capital Structure Change
Shanmuga Hospital's members approved an increase in authorized share capital from ₹14 Crore to ₹25 Crore at the 6th Annual General Meeting.
Shanmuga Hospital Other Announcement
Shanmuga Hospital Limited appointed CS S Anuradha as the Secretarial Auditor for a five-year term starting from FY 2026-27.
- Execution
- 5 years (FY 2026-27 to FY 2030-31)
Shanmuga Hospital Management Change
Shanmuga Hospital Limited has appointed Mrs. S Anuradha as the new Secretarial Auditor. The appointment is for a term of 60 months.
Shanmuga Hospital Annual General Meeting
Shanmuga Hospital Ltd held its 6th Annual General Meeting on September 18, 2026, to discuss financial statements, director appointments, and various capital and ESOP resolutions.
Shanmuga Hospital Promoter Buying: ₹0.13 Cr
Promoter and Director Panneerselvam Prabu Sankar acquired shares of Shanmuga Hospital Ltd through open market purchases worth ₹0.13 Crore, increasing his stake by 0.22%.
- Value
- ₹0.13 Cr
- Promoter stake change
- +0.22%
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.